<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A patient with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in remission developed a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) 12 years after ABMT </plain></SENT>
<SENT sid="1" pm="."><plain>This patient had undergone bone marrow harvesting prior to any chemoradiotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>He had received the autograft following conditioning with high-dose CY and TBI </plain></SENT>
<SENT sid="3" pm="."><plain>Chromosomal analysis of BM cells revealed complicated abnormalities </plain></SENT>
<SENT sid="4" pm="."><plain>Similar karyotypic abnormalities in host-derived BM cells were found in another patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> who had received allogeneic BM following conditioning with CY plus TBI 15 months previously </plain></SENT>
<SENT sid="5" pm="."><plain>These findings suggest that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or clonal karyotypic abnormalities following ABMT may derive from endogenous hematopoietic stem cells that survive the BMT preparative regimen </plain></SENT>
</text></document>